A fast-paced, medical-historical mystery, filled with twists and turns.-Chicago Tribune

Drawing on her years of counseling experience, Gay Hubbard offers practical advice on how to live through loss and pain in redemptive ways.

Reviewing over a century of aspirin research and use, Aspirin and Related Drugs provides a comprehensive source of information on the history, chemistry, absorption in the body, therapeutic effects, toxicology, elimination, and future uses of aspirin. Highlighting the historical evolution of the salicylates and the commercial development of

This volume is a state-of-the art resource on the recent advances and clinical management of NSAIDs and aspirin. The text provides a thorough overview of NSAIDS and aspirin, reviewing such topics as pharmacology and mechanisms, clinical effects, and the safety and efficacy of these drugs. It also focuses on the effect of the drugs on the cardiovascular system and in the prevention of GI cancer. Practical recommendations for a safe prescription of NSAIDs are also included. Written by experts in the field, NSAIDs and Aspirin: Recent Advances and Implications for Clinical Management is a comprehensive text of great value to gastroenterologists, rheumatologists, cardiologists, oncologists, orthopedists, trauma and internal medicine specialists.

The history of competition in the aspirin industry.

“A fascinating history of a public health crisis. Compellingly written and insightful, Keep Out of Reach of Children traces the discovery of Reye’s syndrome, research into its causes, industry’s efforts to avoid warning labels on one suspected cause, aspirin, and the feared disease’s sudden disappearance. Largent’s empathy is with the myriad children and parents harmed by the disease, while he challenges the triumphalist view that labeling solved the crisis.” —ERIK M. CONWAY, coauthor of Merchants of Doubt “Largent’s engaging and honest account explores how medical mysteries are shaped by prevailing narratives about venal drug companies, heroic investigators, and Johnny-come-lately politicians.” —HELEN EPSTEIN, author of The Invisible Cure “Fascinating. . . . Thought-provoking.” —Booklist “Well-researched. . . . A revealing work.” —Kirkus Reviews Reye’s syndrome, identified in 1963, was a debilitating, rare condition that typically afflicted healthy children just emerging from the flu or other minor illnesses. It began with vomiting, followed by confusion, coma, and in 50 percent of all cases, death. Survivors were often left with permanent liver or brain damage. Desperate, terrorized parents and doctors pursued dramatic, often ineffectual treatments. For over fifteen years, many inconclusive theories were posited as to its causes. The Centers for Disease Control dispatched its Epidemic Intelligence Service to investigate, culminating in a study that suggested a link to aspirin. Congress held hearings at which parents, researchers, and pharmaceutical executives testified. The result was a warning to parents and doctors to avoid pediatric use of aspirin, leading to the widespread substitution of alternative fever and pain reducers. But before a true cause was definitively established, Reye’s syndrome simply vanished. A harrowing medical mystery, Keep Out of Reach of Children is the first and only book to chart the history of Reye’s syndrome and reveal the confluence of scientific and social forces that determined the public health policy response, for better or for ill. Mark A. Largent, a survivor of Reye’s syndrome, is the author of Vaccine: The Debate in Modern America and Breeding Contempt: The History of Coerced Sterilization in the United States. He is a historian of science, Associate Professor in James Madison College at Michigan State University, and Associate Dean in Lyman Briggs College at Michigan State University. He lives in Lansing, Michigan.

Winner of the 2018 Arthur J. Viseltear Award from the Medical Care Section of the American Public Health Association​ Children and Drug Safety traces the development, use, and marketing of drugs for children in the twentieth century, a history that sits at the interface of the state, business, health care providers, parents, and children. This book illuminates the historical dimension of a clinical and policy issue with great contemporary significance—many of the drugs administered to children today have never been tested for safety and efficacy in the pediatric population. Each chapter of Children and Drug Safety engages with major turning points in pediatric drug development; themes of children’s risk, rights, protection and the evolving context of childhood; child-rearing; and family life in ways freighted with nuances of race, class, and gender. Cynthia A. Connolly charts the numerous attempts by Congress, the Food and Drug Administration, the American Academy of Pediatrics, and leading pediatric pharmacologists, scientists, clinicians, and parents to address a situation that all found untenable. Open access edition funded by the National Endowment for the Humanities. The text of this book is licensed under a Creative Commons Attribution NonCommercial-NoDerivatives 4.0 International License: https://creativecommons.org/licenses/by-nc-nd/4.0/

Drug-Induced Liver Injury, Volume 85, the newest volume in the Advances in Pharmacology series, presents a variety of chapters from the best authors in the field. Chapters in this new release include Cell death mechanisms in DILI, Mitochondria in DILI, Primary hepatocytes and their cultures for the testing of drug-induced liver injury, MetaHeps an alternate approach to identify IDILI, Autophagy and DILI, Biomarkers and DILI, Regeneration and DILI, Drug-induced liver injury in obesity and nonalcoholic fatty liver disease, Mechanisms of Idiosyncratic Drug-Induced Liver Injury, the Evaluation and Treatment of Acetaminophen Toxicity, and much more. - Includes the authority and expertise of leading contributors in pharmacology - Presents the latest release in the Advances in Pharmacology series

For readers of Bad Blood and Empire of Pain, an authoritative look at monopoly medicine from the dawn of patents through the race for COVID-19 vaccines and how the privatization of public science has prioritized profits over people Owning the Sun tells the story of one of the most contentious fights in human history: the legal right to produce lifesaving medicines. Medical science began as a discipline geared toward the betterment of all human life, but the merging of research with intellectual property and the rise of the pharmaceutical industry warped and eventually undermined its ethical foundations. Since World War II, federally funded research has facilitated most major medical breakthroughs, yet these drugs are often wholly controlled by price-gouging corporations with growing international ambitions. Why does the U.S. government fund the development of medical science in the name of the public only to relinquish exclusive rights to drug companies, and how does such a system impoverish us, weaken our responses to crises, and, as in the cases of AIDS and COVID-19, put the world at risk? Outlining how generations of public health and science advocates have attempted to hold the line against Big Pharma and their allies in government, Alexander Zaitchik’s first-of-its-kind history documents the rise of privatized medicine in the United States and its subsequent globalization. From the controversial arrival of patent-wielding German drug firms in the late nineteenth century to present-day coordination between industry and philanthropic organizations—including the influential Bill & Melinda Gates Foundation—that stymie international efforts to vaccinate the world against COVID-19, Owning the Sun tells one of the most important and least understood histories of our time.

Drug overdose, driven largely by overdose related to the use of opioids, is now the leading cause of unintentional injury death in the United States. The ongoing opioid crisis lies at the intersection of two public health challenges: reducing the burden of suffering from pain and containing the rising toll of the harms that can arise from the use of opioid medications. Chronic pain and opioid use disorder both represent complex human conditions affecting millions of Americans and causing untold disability and loss of function. In the context of the growing opioid problem, the U.S. Food and Drug Administration (FDA) launched an Opioids Action Plan in early 2016. As part of this plan, the FDA asked the National Academies of Sciences, Engineering, and Medicine to convene a committee to update the state of the science on pain research, care, and education and to identify actions the FDA and others can take to respond to the opioid epidemic, with a particular focus on informing FDA's development of a formal method for incorporating individual and societal considerations into its risk-benefit framework for opioid approval and monitoring.